SEOUL, South Korea, March 15, 2024 /PRNewswire/ — Seegene Inc. (KQ096530), a leading South Korean company offering a complete solution for molecular PCR diagnostics, and Springer Nature, a global provider to the study community, unveiled the final list of participants in the progression allocation of diagnostic reagents on March 15, 2024 (GMT), through the Open Innovation Program (https://openinnovation. seegene. com/open-innovation/2023-2024-anuncios/) online platform.
In September 2023, Seegene and Springer Nature opened programs for scientists and experts from the global network to carry out in the 15 projects designated to scale up Seegene’s qPCR syndromic diagnostic assay reagents for the Open Innovation Program.
During the initial paper-assortment phase, a total of 281 programmes from 47 other countries were submitted, demonstrating the overall interest in the programme. Two rounds of assessments were conducted, with the addition of a review of tables and country-specific on-site assessments. A total of 26 programmes were decided upon in the evaluation process. The total number of winners decided is 17, including those who implemented more than one project.
The nominated projects decided and the final number of winners are as follows:
The Open Innovation Program awarded the winners from a total of 12 countries: Belgium (3), Netherlands (1), Germany (2), Italy (3), Portugal (1), Canada (3), Mexico (2), Argentina. (1), United Arab Emirates (3), South Korea (3), Kenya (1) and United Arab Emirates (3). (Numbers in parentheses indicate the number of projects selected)
Winners will receive study grants of up to US$600,000 depending on the project. In addition, Seegene will supply syndromic qPCR reagents, extraction reagents, a progression formula (SGDDS), a tool (AIOS) and related software free of charge for the entire collaboration. out of time.
Developing products that summarize the wisdom and expertise of scientists around the world is key to achieving the global vision: “A global liberation from all diseases. “The first open innovation program marks the first step in this effort.
“By attracting many notable applicants from diverse backgrounds, the assessments provide an invaluable opportunity to tame a strong global network of clinical trial collaborations,” said Dr. Jik Young Park, Head of Development Automation at Seegene. Dr. Park, a member of the committee responsible for reviewing the submitted programs.
The open innovation program is an integral component of Seegene’s broader technology sharing initiative, the SG OneSystem business, which began in 2023 and aligns with the company’s vision of creating a “disease-free world. “
The SG OneSystem business was born from the dissemination of Seegene’s extensive experience and wisdom accumulated over 20 years. The initiative includes collaboration with representative establishments in the country, in order to expand diagnostic products adapted to the wishes of the local market.
In pursuit of this vision, Seegene further strengthened its SG OneSystem business through the strategic collaboration with Microsoft in January 2024, marking a milestone in its commitment to advancing global healthcare solutions. Seegene’s Digital Development System (DSDMS), which allows less experienced researchers to expand testing, will integrate Microsoft Azure services, adding the Azure OpenAI service.
About Seegene
Seegene has 23 years of committed experience in R
Photo: https://mma. prnewswire. com/media/2363395/Seegene_and_Springer_Nature_Announce_Awardees_for_the_Open_Innovation_Program. jpgLogotipo: https://mma. prnewswire. com/media/1357790/Seegene_logo_Logo. jpg
Show content: https://www. prnewswire. co. uk/news-releases/seegene-and-springer-nature-announce-awardees-for-the-open-innovation-program-302090153. html